European Union (Withdrawal) Act
Phillip Lee Excerpts(5 years, 4 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Dr Phillip Lee (Bracknell) (Con)
The task before Members of this House is simple: we must deal with reality not fantasy; we must be honest with ourselves and our constituents; we must decide to lead, not be led; and, above all, we must each make judgments about what is in the best interests of our constituencies and our country without fear or favour. The issue at hand is too important to do otherwise.
I cannot vote for this withdrawal agreement for many reasons, but this evening I will concentrate on just one: neither this Brexit nor any other practical form of it measures up to what was promised in 2016. The fact is that people voted to leave because they were told that by doing so the country would be richer. They were told about £350 million for the NHS, easy access to the single market and easy, deliverable trade deals with the rest of the world. They were told that there would be less immigration, specifically fewer Muslims, as evidenced by the use of a false position on Turkey in the accession process. Finally, they were told that they would regain sovereignty.
I have not been even remotely persuaded that any of these Vote Leave promises have been shown to be deliverable, and neither have an increasing number of my constituents, if recent sophisticated polling is to be believed. Also, I am convinced that our countrymen and women chose leave without really knowing many of the implications. To be honest, I was one of them. I was one of those ignorant people who did not understand the implications, and I point Members to our lack of membership of the European Medicines Agency and the impact that would have on access to new drugs.
If we had gone out and said to the public, “Vote for this deal,” do we really know for sure what the result would have been? I suspect our people would have been less than enthusiastic. In fact, I suggest that the response would have been, “Up yours,” and rightly so. That is why I strongly believe that it would be a supreme act of political fraud to proceed with any practical or legally deliverable form of Brexit without first getting the legitimacy of public consent. Hence I want no part in this act of self-serving political chicanery, or indeed any other future attempts to deliver softer forms of Brexit.
This deal does not do it for me. However, neither does so-called Norway-plus. Norway does not control its borders, Norway pays into EU programmes and Norway is not at the table when the rules are drawn up. Hands up those who think that not controlling immigration or regulations, and paying for the pleasure, was what won the referendum for Vote Leave? For any responsible parliamentarian to contemplate supporting a no-deal Brexit without giving ourselves at least a decade to adjust to that reality is beyond reckless.
Dr Wollaston
Does my hon. Friend think that any responsible Government could in all conscience inflict no deal on their people?
Dr Lee
No, I do not, to be blunt.
There is only one way out of our mess: ask the people to decide and have the final say, and, unlike in 2016, give a choice between two legally and practically deliverable options. It is to say, “We know you wanted to leave and we respect that. However, leaving means this—is that okay?” This time, there should be no tortuous process of subsequently trying to interpret a result. This time, there should be a decision that will be acted on within 24 hours of the result. The clinical equivalent would be to say, “I know you wanted an operation, but having done some further tests, we’ve now realised there is a significant risk that you will be harmed. Do you still want it?”
The Government have clearly worked hard to respect the 2016 referendum vote and to deliver a workable Brexit, but their mandate is exhausted. They need the legitimacy of a new vote. In response to the argument of some colleagues, it is not true to say that the public will never forgive us if we do not deliver Brexit, but it is certainly the case that if we deliver a bad deal, the public should never forgive us. If the public vote for this Brexit, fine, but I am not voting for it, because there has not been informed consent to it, it is not in my constituents’ interests and it is not in my country’s best interests.
Trade Bill
Phillip Lee ExcerptsTuesday 17th July 2018
(5 years, 10 months ago)
Commons ChamberRead Full debate Trade Bill 2017-19 View all Trade Bill 2017-19 Debates Read Hansard Text Read Debate Ministerial Extracts Amendment Paper: Consideration of Bill Amendments as at 17 July 2018 - (17 Jul 2018)
Dr Paul Williams (Stockton South) (Lab)
I do hope that we can vote on new clause 17. NHS patients will not be helped if we leave the European Medicines Agency. Being part of the EMA means that when a new drug is developed, a common set of protocols is followed to get that medicine approved. The UK is a world leader in pharmaceuticals and biomedical sciences. We have been the driving force behind the EMA, which has provided significant employment and revenue here in London, and has helped to raise and maintain standards for patients throughout Europe. We have already lost the EMA to Amsterdam, but although we have lost it geographically, we still have the chance to be part of the European medicines regulatory network partnership, and continue to benefit from the work of the EMA.
There are three big markets for new drugs in the world: the United States, Japan and the EU. Companies already have to follow different processes to get their drugs approved in those countries, but, together with the EU, we are part of a single powerful bloc that represents 22% of the global pharmaceutical market. Companies prioritise getting their drugs to us, because we provide a single European system. If we leave the EMA, we will have only 3% of the global market. Quite simply, we will not be a priority for new drugs. Switzerland and Canada have separate approval systems, and typically get their new drugs six months later than the EU. That is the cost of leaving the EMA: a six-month delay. Try explaining to a patient that a new life-saving cancer drug will not be available to them because we left the EMA!
So why are we leaving? Our life sciences industry is not complaining about EU “red tape”; it likes the common system. According to the Association of the British Pharmaceutical Industry,
“Creating a standalone UK regulator would require significant resource, time and expertise, and...would…still leave the UK behind the US and EU”.
We are leaving the EMA because people voted to leave the EU, but how many people knew that when they voted to leave the EU, they voted to increase the cost of new medicines regulation, a cost that will be passed on to the NHS; to reduce the UK's international influence and excellence in this area of life sciences; and to delay access to new drugs for cancer patients? New clause 17 asks that we “take all necessary steps” to continue to participate in the European medicines regulatory network partnership. We could do that by remaining a member of the EU, by becoming a member of the European Free Trade Association, or by negotiating an associate membership of the EMA.
We are already seeing the high cost of Brexit to the NHS. We are seeing an exodus of EU staff which is making recruitment challenges much harder, we are seeing the threat to the supply chain if we leave the customs union, and now we face delays in the delivery of new drugs to cancer patients. It does not have to be this way. I will be voting for new clause 17 tonight, and I hope that Members in all parts of the House will put the interests of NHS patients above Brexit ideology and join me in voting to remain part of the European medicines regulatory partnership.
Dr Phillip Lee (Bracknell) (Con)
It is a pleasure to follow the hon. Member for Stockton South (Dr Williams), who is a co-signatory to my new clause 17, as are other medically qualified Members: the hon. Member for Central Ayrshire (Dr Whitford) and my hon. Friend the Member for Totnes (Dr Wollaston), the Chairman of the Health Committee.
We all recognise the importance of remaining part of the European medicines regulatory network partnership. New clause 17 would make it a “a negotiating objective” for the Government to secure an agreement that would allow the United Kingdom to continue to participate fully in the partnership. This is vital because it is how we get our people and our NHS the medicines they need. It is also important for our pharmaceutical sector, about which my right hon. Friend the Prime Minister has observed that it is hard to think of an industry of greater strategic importance to Britain and that does so much to improve the lives of patients around the world.
Let me explain further. The European medicines regulatory network partnership makes the process of accessing life-saving new medicines and moving medicines quick and easy. If we leave that partnership, the NHS would get ground-breaking new drugs like those for cancer, dementia and diabetes long after other parts of the world. That is because pharmaceutical companies will apply for licences in the much larger American, European and Asian markets before they come to the UK. It would also be harder to get the medicines we need when we need them. This is particularly worrying for time-critical drugs and equipment. For example, some of the trauma treatments used for victims of last year’s Manchester Arena bombing were stocked in Amsterdam; we got them straightaway because there were no borders or checks. After Brexit we could, in effect, create a hard border so this would not be so easy.
Antoinette Sandbach (Eddisbury) (Con)
AstraZeneca has a supply line of 4,000 people in the north-west. They assist in the manufacturing of a cancer drug that is exported to Europe. Without that export to Europe it would not be viable, because it helps 130,000 people across Europe. Does my hon. Friend agree that remaining in the European Medicines Agency would allow such frictionless trade to carry on?
Dr Sarah Wollaston (Totnes) (Con)
Evidence to the Health and Social Care Committee overwhelmingly showed the importance to patients of our maintaining close regulatory alignment not only here, but across the EU. Does my hon. Friend agree with the Committee that we must do more to publish the contingency planning and the consequences of not maintaining alignment so that the public can see this?
Mr Speaker
Order. We must hear the response to that question, but we must also hear from other Members, including the Father of the House.
Dr Lee
I will be as brief as possible, Mr Speaker.
Yes, I do agree with my hon. Friend’s comments. Every month 45 million patient-packs of medicine go to the EU from the UK and 37 million packs move the other way. It is hard to think of a single other product that illustrates so well the importance of frictionless trade.
This amendment supports the Government’s intentions as explained in the Prime Minister’s Mansion House speech and their White Paper, but we must go further and enshrine them in law because of the very real impact on people’s lives, on the NHS’s ability to operate, on the industry, and on investment in the UK. That is why I will press this new clause to a vote.
I will also support new clause 18 this evening. Yesterday was the worst experience in politics I have had in eight years, and I am sorry that it has changed the dynamic. I started the week intending to support our Prime Minister in her deal and the White Paper. Yesterday changed that, and that is why I will be supporting other colleagues on these Benches when we come to new clause 18 this evening.
Gareth Snell (Stoke-on-Trent Central) (Lab/Co-op)
I shall speak briefly on new clause 11 in my name and the names of 20 of my Co-operative party colleagues—the Co-operative party being the third largest party in this House, despite what some in here say.
New clause 11 simply asks the Secretary of State to make an assessment of slavery and servitude as part of any new trade deals. Modern slavery is a stain on society and we in this country are making great headway in tackling it through the Modern Slavery Act 2015, particularly sections 1 and 54, but, sadly, slavery is all too apparent in some parts of the world. Most people in this room will be wearing an item of clothing that has been made by a slave, and we should be using our international prowess and purchasing power to try to deliver a reduction in slavery and servitude.
Amendment 22, which was very kindly tabled by the hon. Member for Stafford (Jeremy Lefroy), supported by the hon. Member for St Austell and Newquay (Steve Double), relates to trade remedies. The British Ceramic Confederation has worked very hard on this. I shall also be supporting amendment 80, because that will also help to protect our manufacturing base.
Oral Answers to Questions
Phillip Lee Excerpts(6 years, 10 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Ian C. Lucas (Wrexham) (Lab)
5. What support the Government provide to women who lose homes and assets as a result of a prison sentence.
The Parliamentary Under-Secretary of State for Justice (Dr Phillip Lee)
The Justice Department is aware of the link between homelessness and reoffending, which is why we are making sure that we address female offenders’ housing and support needs as an absolute priority.
Ian C. Lucas
The Minister has correctly identified the importance of homelessness in reoffending, but will he give much more detail about what specific assistance is given to individuals who leave prison, who we do not want to see reoffending but who need assistance at a crucial time?
Dr Lee
The community rehabilitation companies and indeed the national probation service are required to provide the services to which the hon. Gentleman refers. I guarantee that the female offenders strategy, which is due to be released by the end of the year, will concentrate primarily on improving that community offering.
Mrs Cheryl Gillan (Chesham and Amersham) (Con)
Thirty-eight per cent of women released from prison have no accommodation arranged for them, and more than 46% of women in prison have experienced domestic violence. The Minister knows that many of the problems associated with women prisoners revolve around their mental health. With increasing evidence that autism is to be found among the female population, will the Minister take advantage of this new set of statistics to look at mental health provision for women leaving prison? That is most important.
Dr Lee
I thank my right hon. Friend for the question. I am responsible not only for women’s justice but for offender health. In September, I will have two roundtable meetings to discuss the current mental health provision, both for men and for women. We are aware that the combination of mental health not being treated properly and addiction not being treated properly are significant contributors towards recidivism.
Mrs Madeleine Moon (Bridgend) (Lab)
Many of the women who are imprisoned have mental health problems. Imprisonment and losing their home and possessions set back their chance of recovery. Will the Minister in his reports pay particular attention to the impact of women with mental health problems when they become homeless and lose all that they have managed to pull together?
Dr Lee
Yes, we will. I am aware that a significant proportion of the female population in prison are victims of very difficult circumstances, be they homelessness, coercive relationships and the like. I confirm that the strategy, as I said previously, will concentrate on improving the community offering so that ultimately these women do not commit offences in the first place.
Philip Davies (Shipley) (Con)
Will the Government confirm that they do not believe in giving prisoners who lose their home any more support than any other person who happens to be in the unfortunate positon of losing their home? Will the Minister confirm that the Government do not believe in giving female prisoners who lose their home more support than male prisoners who lose their home?
Dr Lee
I am very glad to be continuing my brief—my hon. Friend always delivers the question that I expect. I assure him that, with regard to access to housing, I am not aware that ex-offenders will be given any more priority than people who have not committed an offence. With reference to whether we treat men and women who have committed offences equally, I am interested in reducing crime and I am convinced that a disproportionate number of women are committing crime because of the way in which they are treated, be it by their partners or indeed by their housing circumstances. I think he will agree that, if we can get this right, we will be reducing crime, which I think is the best outcome.
Carolyn Harris (Swansea East) (Lab)
Vulnerable women on release are not given adequate support, either with housing or with community reintegration. Many return to abusive relationships, drug and alcohol abuse, and, at worst, crime. Does the Minister honestly believe that we are giving women’s life chances parity of esteem in their current treatment?
Dr Lee
I agree that we are not getting the treatment of women offenders right. That is why I was eager to introduce a new strategy. The Manchester area provides an example of where the Department is investing in a whole system approach. I do not think Whitehall is the place to make decisions on a woman’s future before, during or after prison. I would prefer to localise decision making so that decisions are made by people who understand the women concerned, so that we can keep them in the community and away from prison.
Mr Speaker
We will probably be able to take only the Order Paper questions next, and that must be done briefly.